RHU ORGANOMIC’s Post

🎥 Good news! Our latest webinar is now available to watch on demand! In it, you'll learn all about the latest advancements in organ-on-a-chip for cancer research and drug discovery. This webinar will not only cover capturing the tumor microenvironment (TME) in hepatocellular carcinoma in vitro but will explore how MIMETAS can help put therapeutic targets in immuno-oncology into patient context.   In this webinar, you will: - Gain unparalleled insights into replicating TME dynamics in vitro. - Engage in meaningful dialogue about TME complexities, focusing on angiogenesis, stroma, and immune responses. - Understand the impact of TME variables on the success of existing treatments. - Discover how partnership with MIMETAS can impact your oncology research, speeding up discovery and improving therapy prediction accuracy.   Watch the webinar here: https://lnkd.in/eBpNv8YE #CancerResearch #Immunooncology #OncologyResearch

Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   4. Intravesical portuzumab monatox-qqrs (Vicinium)   Vicinium is a recombinant fusion protein that blocks protein synthesis in order to mediate tumour cell death. The FDA denied approval for its use in BCG-unresponsive non-muscle-invasive bladder cancer following a review of the results of a phase 3 single-arm clinical trial. The 3-month complete response rate was 40%, and 52% of patients who responded remained disease-free for 12 months after treatment.   Tomorrow: IL-15 superagonist + BCG   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   4. Intravesical portuzumab monatox-qqrs (Vicinium)   Vicinium is a recombinant fusion protein that blocks protein synthesis in order to mediate tumour cell death. The FDA denied approval for its use in BCG-unresponsive non-muscle-invasive bladder cancer following a review of the results of a phase 3 single-arm clinical trial. The 3-month complete response rate was 40%, and 52% of patients who responded remained disease-free for 12 months after treatment.   Tomorrow: IL-15 superagonist + BCG   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

📢 Role of #GutMicrobiota in #BreastCancer and Drug Resistance 👨🎓 by Sathiyapriya Viswanathan et al. 🔗 Full article: https://lnkd.in/gEjTGQbp In this review article, the authors discuss the impact of the microbiota on breast cancer, with a primary focus on the gut microbiota’s regulation of the breast cancer microenvironment. Ultimately, updates on how #immunotherapy can affect the breast cancer-based #microbiome and further clinical trials on the breast and microbiome axis may be an important piece of the puzzle in better predicting breast cancer risk and prognosis. 👉 This article belongs to the Special Issue: Role of Microorganisms in Breast Cancer https://lnkd.in/gwZ4R-ns

NEW from #ESMO2024 | NIAGARA: perioperative #durvalumab with neoadjuvant #chemotherapy in MIBC 🎥 🇪🇸 Guru Sonpavde, MD, Adventhealth Cancer Institute, gives an overview of the Phase III NIAGARA trial (NCT03732677), which assessed neoadjuvant #durvalumab plus #chemotherapy followed by radical #cystectomy and adjuvant #durvalumab in #cisplatin-eligible patients with muscle-invasive #bladdercancer (MIBC) 🔦 🌟 A statistically significant improvement in event-free survival and overall survival were reported, highlighting the practice-changing nature of the trial 🌟 Learn more 👉 https://lnkd.in/eqK-UQup #VJOncology #Oncologynews

Targeting the Hallmarks of Cancer has been the long term strategy for beating cancer. Understanding the components of how metastases form is a topic that I took great interest in during my degree. Blocking angiogenesis is a key strategy in cancer treatment. Recent findings show how innovative drugs are cutting off the blood supply to tumors, leading to more targeted and effective therapies. #AngiogenesisInhibition #CancerTherapies" Jayson, G.C., et al. (2016). Antiangiogenic therapy in oncology: Current status and future directions. The Lancet, 388(10043), 518-529. Folkman, J. (2007). Angiogenesis: An organizing principle for drug discovery? Nature Reviews Drug Discovery, 6(4), 273-286. doi:10.1038/nrd2115 Kerbel, R.S. (2008). Tumor angiogenesis. The New England Journal of Medicine, 358(19), 2039-2049. doi:10.1056/NEJMra0706596 Gerriets V, Kasi A. Bevacizumab. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from:

🌟Greetings! --- 💡 If you have unique insights or research findings in the field of tumor therapy, we invite you to submit your work! We will ensure your research is indexed in #PubMed and #Scopus. 📚 New #Commentary sharing! Happy reading! 🎬 The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC) 📖 This commentary highlights the key trials that have set the standard-of-care for front-line aUC treatment and suggestions for choosing different regimens for the appropriate patient. 📝 Authors: Minira Aslanova , Eun-mi (Angel) Yu, MD , Jeanny B. Aragon-Ching * 📚 This article belongs to the special issue Emerging Molecular Targets and Therapies of Genitourinary Tumors (Guest Editor: Alcides Chaux, Department of Scientific Research, Norte University, Paraguay) https://lnkd.in/gvYNtfEE 🔍 Let’s explore this promising field together, sharing knowledge and experiences to drive scientific progress! 😉 Looking forward to seeing your submissions! #Cisplatin-eligible #AvelumabMaintenance #EnfortumabVedotin #Pembrolizumab #Nivolumab

The NeoMono trial #SABCS24 Report with Hans-Christian Kolberg https://buff.ly/3BBzAjU Phase II neoadjuvant study in triple-negative #BreastCancer patients, explored the role of PD-L1 as a biomarker for immune checkpoint inhibitor therapy. Despite the trial’s unique design and high rates of pathologic complete response (PCR), especially among PD-L1 positive patients, no significant treatment interaction was observed. PD-L1 continues to show strong potential as an important biomarker for identifying patients who may benefit from immunotherapy, reinforcing its relevance in guiding treatment decisions. ( Video Journal of Oncology (VJOncology) )

❗Update from #ESMO24 - Upper GI cancer data ❗ In this video, one of two filmed on-site at ESMO, Dr Elizabeth Smyth and Dr Samuel Klempner share their insights into upper GI cancer trial data emerging from the congress and the potential impact on clinical practice. In this video, the experts review data from the following studies: ➡️ Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (Janjigian Y, et al. Abstract 1400O, ESMO 2024 ➡️ Trastuzumab deruxtecan monotherapy and combinations in patients with advanced/metastatic HER2-positive oesophageal, gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric03 (DG-03) (Janjigian Y, et al. Abstract 1401O, ESMO 2024) ➡️Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (Peng Z, et al. Abstract LBA60, ESMO 2024) Watch the video update below 👇 This educational programme is supported by an Independent Educational Grant from Bayer #MedicalEducation #Oncology 📺

▶ Real gains in survival and quality of life for lung cancer patients ◀ This important precision medicine study found that tumor testing +and+ waiting for the results before choosing therapy was superior to starting/changing upon results, with both being superior to starting and ignoring the results. Here at Clarified, we have a running Journal Club, where we share important studies and discuss the findings. Now, we’d like to expand the dialogue and see what you think. To get started, here's this 2023 ASCO JCO study of 500+ advanced non-small-cell lung cancer patients, which highlights the “importance of universal, guideline-concordant, rapid genomic testing in stage IV NSCLC.” >Between six to 13.5 months of improved overall survival >More than six additional months gained in the time to next treatment What made the difference? The early, rapid use of precision oncology testing, followed by guideline-based targeted treatment. As the authors noted, “Molecular profiling panels with rapid turnaround times are essential to optimize patient outcomes and should be standard of care.” Find the study here >>https://lnkd.in/gSmPgW2Q And please share your thoughts or clinical experiences on this topic in the comments – we’d welcome the chance to keep the dialogue going! Howard McLeod Lincoln Nadauld Rajni Natesan, MD, MBA #precisionmedicine #molecularprofiling #precisiononcology #oncology #journalclub #clarifiedprecisionmedicine